Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Price Reduction Rate Lowest for Eli Lilly, Highest for Chemiphar
March 15, 2010
- Don't Create Any More New Medical Schools: AJMC
March 15, 2010
- Astellas to Enhance Oncology Pipeline through TOB of OSI
March 15, 2010
- Double-Digit Price Cuts for 27 Products from 35 Leading Companies
March 15, 2010
- 3 Candidates for JMA President Election
March 15, 2010
- Pfizer Japan: Sales Up 2.6% despite Fall in Sales of Norvasc
March 15, 2010
- Premium Will Be Effective for Expediting Development of New Drugs, Indications: Mr Nagatsuma
March 15, 2010
- Shionogi Licenses Ospemifene from QuatRx
March 15, 2010
- Toyobo's Sales to Top ¥400 Bil. in FY2015 Driven by Life Science Business
March 15, 2010
- Korosho Starts Hearing Major Chain Pharmacy Operators
March 15, 2010
- Clexane Prevents Postoperative VTE in Japanese: sanofi-aventis
March 8, 2010
- Makers Should Change Their Marketing Method: Prof. Koyama
March 8, 2010
- 16th Edition of JP to See Sweeping Revisions of “General Rules for Preparations”
March 8, 2010
- Recommendation of Switching PPIs to OTC Status Withheld Again
March 8, 2010
- New NHI Pricing System to Provide Big Opportunity for CROs: Mr Nakamura
March 8, 2010
- Korosho to Call on Public Hospitals for Earlier Price Settlement
March 8, 2010
- Oxiconazole Recommended for Approval as OTC Drugs for Vaginal Candidiasis
March 8, 2010
- 2-Week Restriction on Prescription Impedes Use of New Drugs: Mr Umeda of PhRMA
March 8, 2010
- Dr Hotta Calls For Flexible Approach to Applications Based on Data from Public Domain
March 8, 2010
- Legislation of “Specific Nurses”Proposed by Korosho
March 8, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…